Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
78
self-reported 51–200 band
Founded
Not recorded
Legal entities
1
ACRA
Office countries
4
4 addresses
Funding rounds
None on record
Company type
Privately Held
self-reported
Legal entity
1 brand → 1 confirmed entity
SCIGEN PTE. LTD.Entity record →
UEN199805796R
Legal entities
Show as table · SciGen Pte. Ltd.: 1 registry entity
| SCIGEN PTE. LTD. | UEN 199805796R |
|---|---|
| Confirmed matches | 1 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
SciGen is a rapidly growing biopharmaceutical company that markets and commercializes innovative and affordable healthcare products worldwide. We leverage our commercialization and networking capabilities to in-licenses and distribute branded pharmaceutical products and medical devices to treat endocrinological and oncological diseases, and continuously fill and improve our pipeline and product portfolio. Founded in the Asian Innovation Capital, Singapore in 1988, we currently have operations in Singapore, South Korea, Australia, China, Philippines and present commercially in all 6 continents. With the exceptional commercialization capabilities, regulatory expertise as well as international management experiences, and strategic partnerships built with industry and academic institutes, we strive to deliver hope and make a real and lasting difference to patients and their families.
Who are we?
- We believe in delivering solutions that matter to the people of today and innovating for the people of tomorrow.
- To us, it is more than a business - it is a mission.
What do we do?
- We combine a specialty pharmaceutical business with a leading biologics biotechnology engine.
- We partner to bring the best drugs we can find to the patients who need it most.
How do we do it?
- Our efforts aim to deliver better patient outcomes through better science.
- We understand that humility and service matter as it is not about us, it is about making patients’ lives better.
Specialties
All 5 specialties
- Endocrinology
- Oncology
- Anti-infectives
- Generic Medicines
- Biosimilars
Locations
4
Countries with an office address4 addresses on record
Country footprint
Show as table · Offices in 4 countries
| Countries | 4 |
|---|---|
| Primary country | SG |
All codes: SG AU KR PH
Addresses
- SG150 Beach Road, #32-05/08 Gateway West; Singapore, 189720Primary
- AUSydney
- PHManila
- KRSeoul
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Counts only. No names are stored here, and none are served.
FAQ
Which legal entity operates under SciGen Pte. Ltd.?
One Singapore entity on ACRA. SCIGEN PTE. LTD. (UEN 199805796R), high confidence.
How many people work at SciGen Pte. Ltd.?
The record holds 78 counted staff profiles at January 2026, inside the self-reported 51–200 band.
Where does SciGen Pte. Ltd. have offices?
Four addresses on record across 4 countries. Primary: 150 Beach Road, #32-05/08 Gateway West, Singapore 189720.
Has SciGen Pte. Ltd. raised funding?
None linked to this brand.
What does SciGen Pte. Ltd. list as its specialties?
Five tags on the brand's own list, among them endocrinology and oncology.
Which companies are listed alongside SciGen Pte. Ltd.?
7 profiles list SciGen Pte. Ltd. as a peer — 79th percentile in Pharmaceutical Manufacturing. It lists ten peers of its own.